Staar Surgical (NSDQ:STAA) this week reported results from the feasibility clinical study of its Evo+ Visian ICL with aspheric optics designed to reduce presbyopia, and that based on the results it plans to launch a pivotal clinical study of the device during the 1st quarter next year.
The Monrovia, Calif.-based company’s EVO+ Visian ICL is designed to be surgically implanted and operate with the patient’s eye to correct vision. The lens is designed to be positioned inside the eye between the iris and natural lens where it stays indefinitely.
Staar Surgical said that it presented results from 24 patients involved in the feasibility study on its investor and analyst day yesterday, according to an SEC filing.
In August, Staar Surgical saw shares rise slightly after the medical device maker met expectations on Wall Street with its 2nd quarter earnings results.
